secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2022-10-14T23:59:59+00:00
Accession:  0001847903-22-000071
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Centessa CMO Javad Shahidi departs; Antoine Yver assumes responsibilities effective Oct 14, 2022
--------------------------------------------------------------------------------

- CMO Javad Shahidi mutually agreed to depart; last day Oct 14, 2022.
- Departure not due to any disagreement regarding operations, policies, or practices.
- Chairman of Development Antoine Yver (30+ yrs drug dev) assumes all CMO responsibilities effective Oct 14.
- Dr. Yver led approvals for 11 drugs including Tagrisso, Lynparza, Enhertu; prior roles at Daiichi Sankyo and AstraZeneca.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/cnta-20221013.htm
  HTML page:      https://secwatch.observer/filing/0001847903-22-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer